Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...
A 68-year-old man presented to the gastroenterology clinic with recurrent melena over 3 months with a history of recurrent spontaneous epistaxis and a familial pattern of similar bleeding among his ...
Opinion
Mitigating the global impact of changing HIV policies in the US: a call for advocacy and action
Key points On Jan. 20, 2025, the incoming United States administration froze all foreign assistance funds for 90 days, including the President’s Emergency Plan for AIDS Relief (PEPFAR) funding.[1][1] ...
Multiple sclerosis (MS) often begins in early adulthood, and symptoms may include fatigue, pain, and mood changes. These may not be outwardly visible but can be deeply disabling.[1][1] Clinicians ...
More than 85 000 (2.3 per 1000) people in Canada have cerebral palsy, a group of disorders resulting from a nonprogressive brain lesion early in life. Seventy-five percent of those living with ...
Delirium occurs in 30%–50% of adults aged 65 years or older admitted to hospital, and may be hypoactive (lethargy, reduced psychomotor functioning), hyperactive (agitation, hallucinations) or mixed.1 ...
Diagnosis of loperamide abuse requires a high index of suspicion Loperamide is not detected by routine drug screens. Typically, a patient with loperamide abuse will have a history of opioid misuse or ...
A 24-year-old man was brought by ambulance to a rural hospital after a motor vehicle collision. On physical examination, he was hemodynamically unstable with a blood pressure of 60/40 mm Hg and a ...
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
Background: Consent forms have become too long and often do little to help people understand the risk elements of their participation in research, instead focusing on risk reduction for research ...
Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are the current GLP1RAs available in Canada. These are approved for the treatment of type 2 diabetes and obesity and have been used ...
Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback